Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.

Do insiders & institutionals believe in SNY or NVO?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts prefer SNY or NVO?

Sanofi currently has a consensus target price of $62.50, suggesting a potential upside of 20.56%. Novo Nordisk A/S has a consensus target price of $145.25, suggesting a potential upside of 120.08%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Novo Nordisk A/S	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Does the media prefer SNY or NVO?

In the previous week, Novo Nordisk A/S had 24 more articles in the media than Sanofi. MarketBeat recorded 45 mentions for Novo Nordisk A/S and 21 mentions for Sanofi. Sanofi's average media sentiment score of 1.14 beat Novo Nordisk A/S's score of 0.81 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	10 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	21 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, SNY or NVO?

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.29B	2.96	$6.02B	$2.49	20.82
Novo Nordisk A/S	$290.40B	1.02	$14.64B	$3.29	20.06

Which has more volatility and risk, SNY or NVO?

Sanofi has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to Sanofi's net margin of 12.77%. Novo Nordisk A/S's return on equity of 84.68% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
Novo Nordisk A/S	34.81%	84.68%	26.29%

Is SNY or NVO a better dividend stock?

Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.8%. Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.5%. Sanofi pays out 59.0% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 49.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Does the MarketBeat Community prefer SNY or NVO?

Novo Nordisk A/S received 382 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.98% of users gave Novo Nordisk A/S an outperform vote while only 60.24% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 50 60.24%	Underperform Votes 33 39.76%
Novo Nordisk A/S	Outperform Votes 432 61.98%	Underperform Votes 265 38.02%

Summary

Novo Nordisk A/S beats Sanofi on 13 of the 21 factors compared between the two stocks.